---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-005965"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:39:24.220531+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study

## Summary
- Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).
- Cash $2.8M at March 31; received $0.7M post-quarter from Canadian govt funding.
- Expanding Phase 3 ARDS trial with EB05; up to C$23M govt support secured.
- Plans to file IND for Phase 2 pulmonary fibrosis study with EB05.
- Seeks U.S. approval for Phase 2 vitiligo study; pursuing strategic deals for EB01.

## SEC filing metadata
- accession: 0001654954-24-005965
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-005965
- JSON: https://secwatch.observer/filing/0001654954-24-005965.json
- Plain text: https://secwatch.observer/filing/0001654954-24-005965.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported the three and six months ended March 31, 2024 results: net income $1.9 million for the quarter ended March 31, 2024, EPS $0.58 per common share.
  - Period: the three and six months ended March 31, 2024
  - Net income: $1.9 million for the quarter ended March 31, 2024
  - EPS: $0.58 per common share
  - Result: reported results
  source text: For the quarter ended March 31, 2024, Edesa reported a net loss of $1.9 million, or $0.58 per common share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm
- Earnings Releases
  Edesa Biotech, Inc. reported the six months ended March 31, 2024 results: net income $3.5 million for the six months ended March 31, 2024, EPS $1.12 per common share.
  - Period: the six months ended March 31, 2024
  - Net income: $3.5 million for the six months ended March 31, 2024
  - EPS: $1.12 per common share
  - Result: reported results
  source text: For the six months ended March 31, 2024, Edesa reported a net loss of $3.5 million, or $1.12 per common share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.